心理药物及其与双相情感障碍中皮质下大脑体积的相互作用:一个ENIGMA大型分析
Sinead King1,2, John O'Connor3, Emma Corley3
1Clinical Neuroimaging Laboratory, Centre for Neuroimaging, Cognition & Genomics (NICOG), College of Medicine Nursing and Health Sciences, University of Galway, Galway, Ireland. sineadking.stanford@gmail.com.
Molecular psychiatry
|January 15, 2026
概括
心理药物使用会影响双相情感障碍 (BD) 中的大脑结构. 这项大型分析发现,没有药物治疗的患者心室和膜扩大,而服用药物治疗的患者显示体积较小,突出显示药物治疗.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 放射学 放射学是一门学科.
背景情况:
- 双极性障碍 (BD) 大脑成像研究显示不一致的结果,经常被心理药物使用所混.
- 了解药物对大脑结构的影响对于BD研究和治疗至关重要.
研究的目的:
- 在一大群双相情感障碍患者中,研究心理药物状态和皮质下大脑体积之间的关联.
- 探索不同的药物分类 (基于综合征和基于神经科学的命名法 - NbN) 如何影响这些关联.
- 为了检查对药物-大脑体积关系的缓和作用.
主要方法:
- 一种超级分析方法汇集了34个研究小组 (ENIGMA双极性障碍工作组) 的2,664名BD患者和4,065名对照 (CN) 的数据.
- 使用标准化的MRI协议来测量皮质下大脑体积.
- 使用线性混合效应回归和适度分析来评估药物状态和体积相关性.
主要成果:
- 与对照组相比,没有药物治疗的BD患者表现出轻度心室扩大和膜体积增加.
- 接受精神药物治疗的患者表现出较小的皮下体积和较大的心室.
- 抗和抗精神病使用与较小的海马和乳头体积相关;NbN分类将"酸"和"多巴胺对抗剂"确定为关键变量.
结论:
- 药物状况与双相情感障碍中皮质下大脑体积变化有显著的关联.
- 基于神经科学的命名 (NbN) 分类为未来的BD神经成像研究提供了有价值的框架.
- 需要进行进一步的纵向研究,以澄清BD中复杂的临床-药物-神经生物学相互作用.
相关概念视频
01:24Mania and Antimanic Drugs: Overview
553
Mania, a psychological condition characterized by elevated mood, increased energy, and reduced sleep need, is part of the bipolar disorder cycle. The exact cause of mania isn't entirely known, but it is thought to be a combination of genetic, environmental, and neurological factors. Bipolar disorder involves alternating manic and depressive episodes. Mood stabilizers like lithium, antipsychotics, and anticonvulsants help manage these episodes. Lithium carbonate is particularly effective as...
553
01:23Antidepressant Drugs: MAOIs and Other Agents
828
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
828
01:28Psychosis and Antipsychotic Drugs: Overview
817
The term "psychosis" refers to a spectrum of mental disorders characterized by abnormal thoughts, perceptions, and behaviors. It can manifest as mood disorders, dementia, delirium with psychotic features, substance-induced psychosis with psychotic features, brief psychotic disorder, delusional disorder, schizoaffective disorder, and schizophrenia. Among all these disorders, schizophrenia is the most common psychotic disorder, affecting 1% of the worldwide population. Psychotic...
817
01:30Bipolar Disorder
625
Bipolar disorder is a chronic mental health condition marked by significant mood fluctuations, including episodes of mania and depression. Elevated energy levels, heightened mood or irritability, impulsive behavior, reduced sleep needs, rapid speech, racing thoughts, inflated self-esteem, and distractibility characterize mania. Individuals with bipolar disorder often alternate between depressive and manic states, with periods of emotional stability lasting an average of six months to a year.
625
01:28Drug Therapy
245
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
245
01:26Psychosis: Goals of Pharmacotherapy
474
Antipsychotic drugs are a crucial treatment method for acute and chronic psychoses, bipolar illness, and behavioral disorders. The selection of these drugs depends on several factors, including the state of the disease, clinical judgment, possible drug interactions, and the patient's sensitivity to adverse effects. In immediate scenarios, such as delirium and dementia, short-term treatment with low doses of high-potency typical or atypical agents can effectively manage symptom exacerbation.
474